AFC-HD Ams Life Science raises mid-year earnings forecast

AFC-HD Ams Life Science announced an upward revision to its consolidated earnings forecast for the second quarter of the fiscal year ending August 2025, initially published on October 15, 2024. The company now projects net sales of JPY16,690 million, up from the previous forecast of JPY16,400 million. Operating profit is expected to increase to JPY1,329 million from JPY1,200 million, while recurring profit is projected at JPY1,366 million compared to the earlier estimate of JPY1,200 million. Net profit attributable to the parent company's shareholders is revised to JPY904 million, a significant increase from the previous forecast of JPY720 million. This translates to earnings per share of JPY64.22, up from JPY51.15. The company attributes the revision to anticipated higher results in net sales, operating profit, recurring profit, and net profit attributable to the parent company's shareholders than previously projected.